Nutex Health, Inc. (NUTX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Nutex Health, Inc. Do?
Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas. Nutex Health, Inc. (NUTX) is classified as a small-cap stock in the Industrials sector, specifically within the Business Services industry. The company is led by CEO Thomas T. Vo and employs approximately 1,150 people. With a market capitalization of $686M, NUTX is one of the notable companies in the Industrials sector.
Nutex Health, Inc. (NUTX) Stock Rating — Reduce (April 2026)
As of April 2026, Nutex Health, Inc. receives a Reduce rating with a composite score of 43.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NUTX ranks #2,538 out of 4,446 stocks in our coverage universe. Within the Industrials sector, Nutex Health, Inc. ranks #408 of 752 stocks, placing it in the lower half of its Industrials peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
NUTX Stock Price and 52-Week Range
Nutex Health, Inc. (NUTX) currently trades at $101.05. The stock lost $4.65 (4.4%) in the most recent trading session. The 52-week high for NUTX is $193.07, which means the stock is currently trading -47.7% from its annual peak. The 52-week low is $45.88, putting the stock 120.2% above its annual trough. Recent trading volume was 126K shares, suggesting relatively thin trading activity.
Is NUTX Overvalued or Undervalued? — Valuation Analysis
Nutex Health, Inc. (NUTX) carries a value factor score of 80/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 4.58x, compared to the Industrials sector average of 28.33x — a discount of 84%. The price-to-book ratio stands at 1.69x, versus the sector average of 2.23x. The price-to-sales ratio is 0.89x, compared to 0.50x for the average Industrials stock. On an enterprise value basis, NUTX trades at 2.80x EV/EBITDA, versus 5.70x for the sector.
Based on these multiples, Nutex Health, Inc. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
Nutex Health, Inc. Profitability — ROE, Margins, and Quality Score
Nutex Health, Inc. (NUTX) earns a quality factor score of 44/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 37.0%, compared to the Industrials sector average of 8.9%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 17.1% versus the sector average of 3.3%.
On a margin basis, Nutex Health, Inc. reports gross margins of 48.2%, compared to 35.8% for the sector. The operating margin is 27.2% (sector: 6.2%). Net profit margin stands at 14.4%, versus 3.9% for the average Industrials stock. Revenue growth is running at 252.0% on a trailing basis, compared to 6.4% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
NUTX Debt, Balance Sheet, and Financial Health
Nutex Health, Inc. has a debt-to-equity ratio of 117.0%, compared to the Industrials sector average of 70.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.41x, indicating strong short-term liquidity. Total debt on the balance sheet is $319M. Cash and equivalents stand at $166M.
NUTX has a beta of 1.37, meaning it is more volatile than the broader market — a $10,000 investment in NUTX would be expected to move 37.2% more than the S&P 500 on any given day. The stability factor score for Nutex Health, Inc. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Nutex Health, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Nutex Health, Inc. reported revenue of $802M and earnings per share (EPS) of $11.13. Net income for the quarter was $157M. Gross margin was 48.2%. Operating income came in at $246M.
In FY 2025, Nutex Health, Inc. reported revenue of $875M and earnings per share (EPS) of $11.13. Net income for the quarter was $180M. Gross margin was 50.8%. Revenue grew 82.4% year-over-year compared to FY 2024. Operating income came in at $276M.
In Q3 2025, Nutex Health, Inc. reported revenue of $268M and earnings per share (EPS) of $8.27. Net income for the quarter was $97M. Gross margin was 57.8%. Revenue grew 239.9% year-over-year compared to Q3 2024. Operating income came in at $130M.
In Q2 2025, Nutex Health, Inc. reported revenue of $244M and earnings per share (EPS) of $-2.95. Net income for the quarter was $16M. Gross margin was 51.2%. Revenue grew 220.7% year-over-year compared to Q2 2024. Operating income came in at $34M.
Over the past 8 quarters, Nutex Health, Inc. has demonstrated a growth trajectory, with revenue expanding from $76M to $802M. Investors analyzing NUTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
NUTX Dividend Yield and Income Analysis
Nutex Health, Inc. (NUTX) does not currently pay a dividend. This is common among smaller companies in the Business Services industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Industrials dividend stocks may want to explore other Industrials stocks or use the stock screener to filter by dividend yield.
NUTX Momentum and Technical Analysis Profile
Nutex Health, Inc. (NUTX) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
NUTX vs Competitors — Industrials Sector Ranking and Peer Comparison
Within the Industrials sector, Nutex Health, Inc. (NUTX) ranks #408 out of 752 stocks based on the Blank Capital composite score. This places NUTX in the lower half of all Industrials stocks in our coverage universe. Key competitors and sector peers include South Bow Corp (SOBO) with a score of 56.5/100, TSAKOS ENERGY NAVIGATION LTD (TEN) with a score of 61.4/100, Great Lakes Dredge & Dock CORP (GLDD) with a score of 56.7/100, Tri Pointe Homes, Inc. (TPH) with a score of 57.3/100, and Clear Channel Outdoor Holdings, Inc. (CCO) with a score of 52.2/100.
Comparing NUTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NUTX vs S&P 500 (SPY) comparison to assess how Nutex Health, Inc. stacks up against the broader market across all factor dimensions.
NUTX Next Earnings Date
No upcoming earnings date has been announced for Nutex Health, Inc. (NUTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy NUTX? — Investment Thesis Summary
The quantitative profile for Nutex Health, Inc. suggests caution. The value score of 80/100 suggests attractive pricing relative to fundamentals. High volatility (stability score 21/100) increases portfolio risk.
In summary, Nutex Health, Inc. (NUTX) earns a Reduce rating with a composite score of 43.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NUTX stock.
Related Resources for NUTX Investors
Explore more research and tools: NUTX vs S&P 500 comparison, top Industrials stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NUTX head-to-head with peers: NUTX vs SOBO, NUTX vs TEN, NUTX vs GLDD.